BMY vs CTMX · P/E 17, rev $24.46B vs rev $11.7M
Bristol-Myers Squibb Company (BMY) versus CytomX Therapeutics Inc (CTMX) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
CytomX Therapeutics Inc (CTMX) is a biotechnology company listed on US.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported CTMX revenue for 2026-06-30 was $11.7M. Net income was -$38.9M. Revenue was up 13.8% from 2026-03-31 to 2026-06-30. CTMX currently screens at market cap $653.1M.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. CTMX currently screens at market cap $653.1M.
Not investment advice. Open the BMY and CTMX stock pages for the full models.
Not investment advice.